|Articles|July 19, 2023

WuXi STA Launches Injectable Manufacturing Line

The debut will be the CDMO’s first fully automated sterile injectable manufacturing line at the Wuxi, China site.

WuXi STA—a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry—launched its first high potency (HP), fully automated sterile injectable manufacturing line at its drug product site in Wuxi, China.

With an annual capacity of 12 million units, the new HP injectable manufacturing line is expected to further enhance the company's manufacturing capabilities and capacity for injectable dosage forms. This expansion allows the company to adeptly respond to the increasing demand of the high potency pharmaceuticals market.

Meeting occupational exposure limits (OEL) as low as 10 ng/cubic meter, the new HP injectable manufacturing line utilizes fully enclosed isolation systems and automated filling machines. According to the CDMO, the design effectively minimizes human intervention, preventing cross-contamination and ensuring quality assurance for sterile products. The line is equipped with two 20 square-meter lyophilizers, and supports liquid and lyophilized vials of various specifications, with a filling rate of up to 200 units per minute.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.